Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care

Weymann, Deirdre; Laskin, Janessa; Jones, Steven J.M.; Roscoe, Robyn; Lim, Howard John; Renouf, Daniel J.; Schrader, Kasmintan A.; Sun, Sophie; Yip, Stephen; Marra, Marco A.; Regier, Dean A.

doi:10.1007/s12687-021-00557-w

Cited by 6 publications

(9 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common type of cancer studied was breast cancer; one article focused on screening, while the others focused on various stages and types, for example, early stage, metastatic, or hormone receptor-positive breast cancer [ 18 , 22 , 24 , 26 , 30 , 36 ]. Other studies focused on metastatic colorectal cancer (mCC) [ 25 , 34 ], metastatic renal cell carcinoma (mCRC) [ 31 , 32 ], diffuse large B-cell lymphoma [ 28 , 29 ], bronchioalveolar carcinoma (BCCA) stage IIB/IV [ 20 , 21 ], as well as advanced pancreatic cancer [ 17 ], lung cancer [ 19 ], ovarian cancer stage IIC/IV [ 23 ], low-risk thyroid cancer [ 27 ], prostate cancer [ 33 ], advanced stage Hodgkin’s lymphoma [ 35 ], hepatocellular carcinoma [ 37 ], and metastatic, incurable cancer types [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

“…A majority (nine) of studies measured effectiveness in both QALYs and LYs [ 17 , 22 , 24 , 25 , 26 , 28 , 32 , 34 , 37 ]. Six of the studies measured effectiveness in only LYs, [ 20 , 21 , 23 , 29 , 31 , 38 ] while four measured in only QALYs [ 18 , 19 , 33 , 35 ]. Two utilized chemotherapy use rates as their measure of effectiveness [ 30 , 36 ], and one utilized rate of recurrence [ 27 ].…”

Section: Resultsmentioning

confidence: 99%

“…All of the studies included were published between 2012 [ 28 ] and 2022 [ 17 , 22 , 36 ]. While the majority of papers (59%) looked at the real-world cost effectiveness of drugs on cancer, 41% focused on other aspects of cancer care: 7 on screening methods [ 18 , 19 , 23 , 24 , 30 , 36 , 38 ], 1 on preventing recurrence [ 27 ], and 1 on assistive surgery [ 33 ].…”

Section: Resultsmentioning

confidence: 99%

“…ΔEs involving QALYs for non-drug therapies ranged from 0.027 [ 18 ] to 0.0662 [ 33 ]. Only one study investigated LYs for non-drug therapies which resulted in a ΔE of 0.0025 [ 38 ] ( Table 3 ).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada

et al. 2022

View full text Add to dashboard Cite

Cost-effectiveness analysis (CE Analysis) provides evidence about the incremental gains in patient outcomes costs from new treatments and interventions in cancer care. The utilization of “real-world” data allows these analyses to better reflect differences in costs and effects for actual patient populations with comorbidities and a range of ages as opposed to randomized controlled trials, which use a restricted population. This rapid review was done through PubMed and Google Scholar in July 2022. Relevant articles were summarized and data extracted to summarize changes in costs (in 2022 CAD) and effectiveness in cancer care once funded by the Canadian government payer system. We conducted statistical analyses to examine the differences between means and medians of costs, effects, and incremental cost effectiveness ratios (ICERs). Twenty-two studies were selected for review. Of those, the majority performed a CE Analysis on cancer drugs. Real-world cancer drug studies had significantly higher costs and effects than non-drug therapies. Studies that utilized a model to project longer time-horizons saw significantly smaller ICER values for the treatments they examined. Further, differences in drug costs increased over time. This review highlights the importance of performing real-world CE Analysis on cancer treatments to better understand their costs and impacts on a general patient population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada

et al. 2022

View full text Add to dashboard Cite

show abstract

“…9 Although, the emerging economic evidence remains uncertain, we summarize some of the key findings from economic reviews 31,40,65 and budget impact studies about CGP and similar NGS technologies focused on Canadian jurisdictions. 9,27,66 Reviews have highlighted challenges in assessing the economic evidence for CGP and other NGS tests because there are varied comparators used across studies. For example, CGP may be compared with single-biomarker assays, serial testing, or no genetic testing in different situations.…”

Section: Economic Evidencementioning

confidence: 99%

An Overview of Comprehensive Genomic Profiling Technologies to Inform Cancer Care

Basharat¹,

Farah²

2022

cjht

View full text Add to dashboard Cite

Horizon Scan reports provide brief summaries of information regarding new and emerging health technologies; Heath Technology Update articles typically focus on a single device or intervention. This Horizon Scan summarizes the available information regarding emerging comprehensive genomic profiling (CGP) technologies for informing cancer treatments. These technologies are based on next-generation sequencing platforms, which can characterize up to hundreds of genes and other genomic information with a single sample. Emerging tests are also compatible with minimally invasive liquid biopsies that use fluids such as blood samples to support clinical decision-making. CGP could be an alternative or a complement to conventional testing that uses single-biomarker assays or limited gene panels. Some emerging CGP tests available in Canada, the US, and Europe are being considered to inform the treatment of non–small cell lung cancer (NSCLC) because it has the highest number of identified biomarkers. Most identified studies have examined CGP use with NSCLC. The emerging evidence about the clinical and cost-effectiveness of CGP technologies for either NSCLC or other cancer types remains uncertain. Without randomized trials and robust study designs, it is not yet well-established whether the additional costs and technical requirements of CGP may provide better clinical outcomes compared with conventional molecular testing. This Horizon Scan also provides considerations for health systems about testing infrastructure, training for health care professionals, and understanding different patients’ perspectives should CGP or other next-generation sequencing technologies become more widely used in Canada.

show abstract

Resource allocation in genetic and genomic medicine

et al. 2022

View full text Add to dashboard Cite

show abstract

Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care

Cited by 6 publications

References 57 publications

Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada

Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada

An Overview of Comprehensive Genomic Profiling Technologies to Inform Cancer Care

Resource allocation in genetic and genomic medicine

Contact Info

Product

Resources

About